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Background: For patients who remain with involved resection margins after transoral robot-assisted salvage surgery
(TORS) for recurrent squamous cell carcinoma (SCC) at the base of tongue (BOT) following primary (chemo)radiotherapy,
further adjuvant treatment options are very limited. We want to report on our preliminary experience with a new adjuvant
strategy using postoperative temoporfin-mediated photodynamic therapy for this indication.
Methods: Two patients with recurrent SCC after primary (chemo)radiotherapy of the BOT were treated with TORS, but
unfortunately remained with involved resection margins on the postoperative pathology report. If left without additional
treatment, these patients are prone to further recurrence. Temoporfin-mediated photodynamic therapy was used as a
new adjuvant approach to treat the remaining microscopic disease at the resection margins.
Results: Good oncological and functional results were obtained in these patients, now treated for a recurrence, after a
preceding full course of radiotherapy. Both are disease free at 42 and 24 months of follow-up and are able to speak,
breathe, and eat normally.
Conclusions: In selected patients that have undergone salvage surgery with positive resection margins, postoperative
temoporfin-mediated photodynamic therapy can result in a good oncological and functional outcome.
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Intensity-modulated radiotherapy (IMRT) with or without
concomitant chemotherapy is now the standard of care
for locoregionally advanced base of tongue squamous cell
carcinoma (BOT-SCC) [1, 2]. “Resectable” locoregional re-
currence following IMRT requires surgical salvage. This
possibly implies a laryngectomy to avoid aspiration or a
mandibulotomy for access and reconstruction. Recently,
for selected patients, these open approaches have been re-
placed by transoral CO2 laser microsurgery [3] and trans-
oral robotic surgery (TORS), [4] with better function and* Correspondence: vincent.vanderpoorten@uzleuven.be
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creativecommons.org/publicdomain/zero/1.0/cosmesis. This postradiotherapy setting entails more diffi-
cult peroperative margin assessment than in primary
surgery, and not infrequently involved resection margins
on the definitive pathology report. Adjuvant treatment
options to control this remaining microscopic disease are
limited. It is often unclear where further meaningful sur-
gery can be performed. Re-irradiation carries a low chance
of disease control and additional toxicity. Temoporfin-
mediated photodynamic therapy (PDT) has been de-
scribed to effectively control recurrent SCC following
radiotherapy [5, 6]. This is the first report of the use of
PDT as a postoperative adjuvant treatment in patients
with involved resection margins after TORS salvage sur-
gery for post(chemo)radiotherapy recurrent BOT-SCC.Access article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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Two patients with recurrent BOT-SCC after primary
curative-intent treatment with radiotherapy (patient 1)
or concomitant chemoradiotherapy (patient 2) were of-
fered salvage TORS. Unfortunately, definitive pathology re-
vealed involved resection margins. Both patients consented
to postoperative PDT to address this issue. The institu-
tional review board (Ethische Commissie UZ Leuven -
Toetsingscommissie Klinisch Onderzoek) approved of a
retrospective evaluation of their oncologic and functional
outcome (IRB S56521).
TORS
The Laryngeal Advanced Retractor System (LARS, Fentex®,
Tuttlingen, Germany) and the Da Vinci S surgical robot
(Intuitive Surgical® Inc, Sunnyvale, CA, USA), equipped
with the 0-degree endoscope, a 5-mm Maryland dissector,
and a 5-mm monopolar cauter spatula, were used to do the
TORS procedure.
Temoporfin-mediated PDT
Ninety-six hours following slow intravenous injection of
Temoporfin (Foscan®) at a dose of 0.15 mg per kg, under
general anesthesia, the surface of the resected tumor in-
cluding a 1-cm margin was illuminated. We used a diode
laser (652 nm wavelength) at a light dose of 20 J/cm2
and an intensity of 100 mW/cm2 through a microlens
fiber (Biolitec, Jena, Germany). The target area was illu-
minated through a distendible laryngoscope (Karl Storz,
Tuttlingen, Germany), shielding normal tissue around
the target area. Postoperatively, patients made a gradual
return to unrestricted indoor light exposure over a
period of 2 weeks, with an increase of 100 Lux per day.
Results
Patient 1
In 2009, a 61-year-old male with a smoking history of
40 pack-years and a drinking record of 6 units of alcohol
per day for 40 years, was diagnosed with an SCC metastatic
right-sided cervical lymph node. Lacking primary tumor
localization on positron emission tomography-computer
tomography (PET-CT), a bilateral tonsillectomy and a right
modified radical neck dissection were performed in a re-
gional hospital. Three of 20 removed lymph nodes con-
tained SCC, but no primary tumor was found. Postoperative
radiotherapy was given to the nasopharynx, oropharynx, hy-
popharynx, and the bilateral neck (24 fractions of 2 Gray
(Gy)) and a boost (6 fractions of 2 Gy) to the right neck.
One year later, he presented to us with a painful ulcer-
ation in the middle of the BOT. MRI confirmed a super-
ficial ulceration. PET-CT excluded regional or distant
metastases. A biopsy revealed a poorly differentiated
SCC (stage rT1N0M0—Fig. 1a). The multidisciplinary
treatment (MDT) board decided to offer salvage TORSfor this recurrent BOT-SCC, during which there was sat-
isfactory visualization of the tumor and macroscopically
widely free resection margins. The patient resumed oral
feeding on postoperative day 7 and left the hospital on
day 8. The pathology report revealed poorly differenti-
ated SCC with lymphovascular invasion. There was a
widely negative deep margin but, unexpectedly, involved
lateral resection margins due to scattered subepithelial
lobular tumor nests. Redo surgery with expansion of the
margins was judged to unlikely achieve free margins at a
definite risk of considerable functional impairment. Dis-
cussing re-irradiation and temoporfin-mediated PDT as
adjuvant options, the patient chose to undergo PDT. A
tracheotomy was performed and the BOT was illumi-
nated using four consecutive spots (diameter 2.5 cm—o-
verlap 1 cm). Total energy delivered was 400 J.
Despite the negative pretreatment PET-CT, a CT of
the neck, taken at day 12 following PDT because of an
acute episode of pain, unexpectedly revealed an 8-mm
centrally necrotic lymph node in zone Ib in the exten-
sively operated and radiated neck. Needle aspiration bi-
opsy proved SCC, so 17 days after PDT, the metastatic
lymph node was removed. On that day 17, the nasogas-
tric tube (NGT) was removed and on day 19, the tra-
cheal cannula was removed and the patient discharged
from the hospital. Since then, the patient speaks, eats,
and drinks normally and remains disease-free at
42 months of follow-up (Fig. 1b).
Patient 2
Patient 2 is a 64-year-old female, diagnosed in 2011 with a
moderately differentiated SCC of the lingual epiglottis ex-
tending in the BOT and a right-sided metastatic lymph
node (stage T2N1M0). Her medical history involved mor-
bid obesity, arterial hypertension, type II diabetes, moder-
ate renal insufficiency, 46 pack-years, and a history of
2 units of alcohol per day for 40 years. She was treated in
a regional hospital with IMRT to a total dose of 70 Gy
(50 Gy in fractions of 2 Gy with a boost of 20 Gy on the
supraglottis and the cervical lymph nodes) combined with
2 cycles of Cisplatin. The third cycle was canceled because
of neutropenia and progressive renal failure.
Fourteen months later, a recurrent SCC in the right
vallecula and lingual epiglottis with pre-epiglottic space
extension was diagnosed (Fig. 2a). PET-CT additionally
revealed a suspect right-sided level III lymph node. The
MDT board decided to perform, in a first stage, TORS
salvage supraglottic laryngectomy, including the vallec-
ula, leaving the patient to recover from this surgery. In a
second stage, it was planned to address the right-sided
level III lymph node by a superselective neck dissection.
TORS went well, with satisfactory visualization of the
tumor and macroscopically widely free resection mar-
gins. Oral feeding was resumed 5 days postoperatively;
Fig. 1 Patient 1. a Pretreatment axial contrast-enhanced fat-suppressed T1-weighed MR image shows small, irregular ulceration on the BOT
midline. b Axial contrast-enhanced CT image: the BOT at 20 months post-TORS–post-PDT
Fig. 2 Patient 2. Pretreatment sagittal contrast-enhanced CT-image
shows ulceration with marginal enhancement in the BOT midline
(arrowheads); the soft tissue thickening extends on the lingual surface
of the epiglottis (curved arrow)
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home on day 16, still tracheostomy dependent. Unfortu-
nately, definitive pathology revealed a poorly differenti-
ated SCC with a few very small tumor strands extending
at different areas of the specimen into the margins. The
MDT board concluded to associate postoperative adju-
vant PDT of the primary site to the planned neck dissec-
tion. At 8 weeks, the superselective neck dissection
(levels III and IV) revealed 1 metastatic node out of 17
removed lymph nodes. One week later, PDT of the BOT
primary tumor bed, by one spot with a diameter of
3.0 cm to a total energy of 141 J, was performed. Postop-
eratively, the patient continued normal oral feeding. On
post-PDT day 4, the tracheal cannula, in place since the
TORS, could be removed and the patient was discharged
home. At 24 months of follow-up, the patient is speak-
ing, eating, and drinking normally and remains without
disease activity (Additional file 1 Video 1).
Discussion
In the salvage setting of recurrent BOT-SCC, the com-
bination of TORS and adjuvant PDT for involved mar-
gins has not been previously described. Our preliminary
experience in two consecutive patients with recurrent
BOT-SCC following (chemo)radiation suggests that this
approach can achieve locoregional tumor control, while
preserving speech, respiration, and swallowing. In these
patients, treated for a recurrence after a previous full
course of radiotherapy, we left an interval between the
surgery to the primary tumor and the neck to facilitate
resumption of breathing and swallowing. We secured
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the upper airway and aspiration can be expected after
both TORS and PDT, especially in the postradiotherapy
setting. For the same reason, it is safe to incorporate a
4- to 6-week recovery period after TORS, before pro-
ceeding to PDT. Expecting severe interference with the
swallowing mechanism, NGT feeding is often necessary
to ensure adequate caloric intake following TORS and
PDT. The NGT could be removed 7 days after TORS
and 19 days after PDT in patient 1 and 15 days after
TORS in patient 2. In the latter patient, observing no
important dysphagia after PDT, oral feeding was not
interrupted. At hospital discharge after PDT, at 19 days
in patient 1 and at 4 days in patient 2, both were able to
eat, breathe, and speak normally. Follow-up visits were
performed every 2 months for the first 2 years, and for
patient 1, every 3 months in the third year and every
4 months in the fourth year of follow-up [7]. In patients
with involved margins in a previously irradiated area, the
observed oncological disease control, at 42 months for
patient 1 and at 24 months for patient 2, would have
been very unlikely without adjuvant PDT.Conclusions
Temoporfin-mediated PDT seems a meaningful adjuvant
treatment with good oncological and functional results in
selected patients, undergoing salvage TORS for recurrent
BOT-SCC after primary (chemo)radiotherapy. The condi-
tion is that the microscopical remnant disease (R1 margin)
can be fully illuminated during PDT. This approach merits
further study concentrating on long-term locoregional con-
trol and functional outcome in larger groups of patients.Additional files
Additional file 1: Video 1. Indirect laryngoscopic view of the BOT,
supraglottis, and glottis at 12 months after TORS and PDT of recurrent
SCC in the right-sided vallecula and lingual epiglottis in patient 2.
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